Enanta Pharmaceuticals Inc
Company Profile
Business description
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Contact
4 Kingsbury Avenue
WatertownMA02472
USAT: +1 617 607-0800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2027
Employees
120
Stocks News & Analysis
stocks
3 charts on Anthropic’s historic IPO filing
stocks
Weight loss drugs not an existential threat to undervalued ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,971.40 | 2.60 | 0.03% |
| CAC 40 | 7,892.69 | 5.55 | 0.07% |
| DAX 40 | 25,669.42 | 78.65 | 0.31% |
| Dow JONES (US) | 52,441.34 | 63.77 | 0.12% |
| FTSE 100 | 10,705.10 | 18.56 | 0.17% |
| HKSE | 23,094.83 | 53.51 | 0.23% |
| NASDAQ | 26,477.17 | 0.64 | -0.00% |
| Nikkei 225 | 63,954.19 | 685.82 | 1.08% |
| NZX 50 Index | 13,691.33 | 11.06 | 0.08% |
| S&P 500 | 7,728.53 | 5.93 | 0.08% |
| S&P/ASX 200 | 8,847.30 | 2.80 | -0.03% |
| SSE Composite Index | 3,681.47 | 33.17 | 0.91% |